TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer

Weiwei Nie; Weisun Huang; Wenwen Zhang; Jing Xu; Wei Song; Yanru Wang; Aiyu Zhu; Jiayan Luo; Guichun Huang; Yucai Wang; Xiaoxiang Guan

doi:10.18632/oncotarget.3096

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer

Weiwei Nie, Weisun Huang, Wenwen Zhang, Jing Xu, Wei Song, Yanru Wang, Aiyu Zhu, Jiayan Luo, Guichun Huang, Yucai Wang and Xiaoxiang Guan _

PDF | HTML | How to cite

Oncotarget. 2015; 6:3003-3012. https://doi.org/10.18632/oncotarget.3096

Metrics: PDF 2756 views | HTML 2376 views | ?

Abstract

Weiwei Nie1,*, Weisun Huang1,*, Wenwen Zhang2, Jing Xu2, Wei Song1, Yanru Wang1, Aiyu Zhu1, Jiayan Luo2, Guichun Huang2, Yucai Wang3 and Xiaoxiang Guan1,2

1 Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, P.R. China

2 Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, P.R. China

3 Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA

* These authors contributed equally to this work

Correspondence:

Xiaoxiang Guan, email:

Keywords: TXNIP, p27, Her-1/2 inhibitor, breast cancer

Received: November 07, 2014 Accepted: December 24, 2014 Published: December 30, 2014

Abstract

Previous studies have indicated that Her-2 induction causes a strong decrease in thioredoxin interaction protein (TXNIP) in breast cancer cells. However, little is known regarding the prognostic value of TXNIP in clinical breast cancer patients with anti-Her-2 treatment. Using a tissue microarray, we detected TXNIP and p27 expression in breast cancer tissue, as well as corresponding noncancerous tissues. We found that TXNIP expression was associated with better overall survival (OS) in these 150 breast cancer patients and that TXNIP and Her-2 expression status were significantly inversely correlated (r=-0.334, P<0.001). These results were validated in another 101 breast cancer tissue samples (r=-0.422, P<0.001). Moreover, TXNIP expression increased significantly following treatment of the human breast cancer cell lines BT474 and SK-BR-3 with a Her-1/2 inhibitor. Furthermore, TXNIP transfection induced p27 expression and G1 cell cycle arrest and apoptosis. Taken together, our findings suggest that TXNIP plays a critical role in anti-Her-1/Her-2 treatment and may be a potential prognostic marker in breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3096

Publication Alerts

Research Papers:

TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer

Abstract